

DIVI'S LABORATORIES LIMITED**UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31st DECEMBER, 2011**

(Rs.in Lakhs)

| | Particulars | STANDALONE | | | | | Year Ended |
|----|--|---------------|--------------|--------------|---------------|--------------|---------------|
| | | Quarter ended | | | Period ended | | |
| | | 31.12.2011 | 30.09.2011 | 31.12.2010 | 31.12.2011 | 31.12.2010 | |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited | |
| | (1) | (2) | (3) | (4) | (5) | (6) | (7) |
| 1 | (a) Net Sales/Income from operations (Net of Excise Duty) | 41468 | 35408 | 31005 | 112731 | 82590 | 130544 |
| | (b) Other Operating Income | 274 | 40 | 492 | 629 | 830 | 958 |
| | Total Income | 41742 | 35448 | 31497 | 113360 | 83420 | 131502 |
| 2 | Expenditure: | | | | | | |
| | a. (Increase) / Decrease in Stock-in-Trade and Work-in-Progress | (4242) | (469) | 1105 | (8337) | 558 | 3452 |
| | b. Consumption of Raw Material | 20403 | 14893 | 10741 | 53204 | 31774 | 48668 |
| | c. Purchase of Traded Goods | 0 | 0 | 0 | 0 | 0 | 0 |
| | d. Employees Cost | 3590 | 3237 | 2745 | 10123 | 7542 | 11206 |
| | e. Depreciation | 1620 | 1520 | 1352 | 4540 | 3990 | 5335 |
| | f. Other Expenditure | | | | | | |
| | - Manufacturing Expenses | 3745 | 3066 | 2669 | 9805 | 7311 | 10207 |
| | - Other expenses | 3136 | 2060 | 1889 | 7705 | 4954 | 7565 |
| | g. Total | 28252 | 24307 | 20501 | 77040 | 56129 | 86433 |
| 3 | Profit from Operations before Other Income, Interest & Exceptional Items (1-2) | 13490 | 11141 | 10996 | 36320 | 27291 | 45069 |
| 4 | Other Income | 2570 | 2234 | 709 | 6130 | 1979 | 2902 |
| 5 | Profit before Interest & Exceptional Items (3+4) | 16060 | 13375 | 11705 | 42450 | 29270 | 47971 |
| 6 | Finance Charges | 20 | 59 | 56 | 101 | 163 | 66 |
| 7 | Profit after Interest but before Exceptional Items (5-6) | 16040 | 13316 | 11649 | 42349 | 29107 | 47905 |
| 8 | Exceptional items | 0 | 0 | 0 | 0 | 0 | 0 |
| 9 | Profit from ordinary activities before Tax (7-8) | 16040 | 13316 | 11649 | 42349 | 29107 | 47905 |
| 10 | Tax Expense | | | | | | |
| | - Current Tax | 3040 | 2445 | 1190 | 7950 | 2600 | 3920 |
| | - MAT Credit Utilisation | 366 | 125 | 111 | 751 | 184 | 128 |
| | - Deferred Tax | 379 | 141 | 191 | 529 | 241 | 300 |
| 11 | Net Profit from ordinary activities after Tax: (9-10) | 12255 | 10605 | 10157 | 33119 | 26082 | 43557 |
| 12 | Extra-ordinary items | 0 | 0 | 0 | 0 | 0 | 0 |
| 13 | Net Profit (+)/Loss(-) for the period (11-12) | 12255 | 10605 | 10157 | 33119 | 26082 | 43557 |
| 14 | Paid-up Equity Share Capital (Face Value: Rs.2 each) | 2654 | 2653 | 2651 | 2654 | 2651 | 2652 |
| 15 | Reserves excluding revaluation | | | | | | 180153 |



| | | | | | | | |
|----|---|----------|----------|----------|----------|----------|----------|
| | reserves | | | | | | |
| 16 | Earnings per Share | | | | | | |
| a) | Basic Earnings Per Share before extra-ordinary items Rs. | 9.24 | 8.00 | 7.68 | 24.97 | 19.71 | 32.90 |
| | Diluted Earnings Per Share before extra-ordinary items Rs. | 9.24 | 7.99 | 7.67 | 24.97 | 19.70 | 32.88 |
| b) | Basic Earnings Per Share after extra-ordinary items Rs. | 9.24 | 8.00 | 7.68 | 24.97 | 19.71 | 32.90 |
| | Diluted Earnings Per Share after extra-ordinary items Rs. | 9.24 | 7.99 | 7.67 | 24.97 | 19.70 | 32.88 |
| 17 | Public shareholding: | | | | | | |
| | - No. of shares | 63481010 | 63454450 | 63380320 | 63481010 | 63380320 | 63372210 |
| | - % of shareholding | 47.84% | 47.83% | 47.81% | 47.84% | 47.81% | 47.79% |
| 18 | Promoters and promoter group shareholding: | | | | | | |
| a) | pledged / encumbered | Nil | Nil | Nil | Nil | Nil | Nil |
| b) | non-encumbered: | | | | | | |
| | No. of shares | 69222100 | 69222100 | 69185100 | 69222100 | 69185100 | 69222900 |
| | Percentage of shares (as a % of the total shareholding of the promoter group) | 100% | 100% | 100% | 100% | 100% | 100% |
| | Percentage of shares (as a % of the total share capital of the company) | 52.16% | 52.17% | 52.19% | 52.16% | 52.19% | 52.21% |

NOTES:

- The above results for the period ended 31st December 2011, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 28th January, 2012 and were subjected to 'limited review' by the Auditors.
- The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
- As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited Standalone Results and to publish consolidated results at the year end.
- Accounts have been reclassified as per the revised Schedule VI to Companies Act, 1956. Directors' Remuneration which was included earlier under Other Expenditure has now been included under Employee Cost. Figures for the previous year/periods have also been regrouped or recasted, wherever necessary.
- During the current quarter, the company has allotted 26,560 equity shares of Rs.2/- each to the employees on exercise of their stock options.
- Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 31.12.2011:
Opening: Nil, Received during the Quarter: 15, Resolved: 15, Closing: Nil

Place: Hyderabad
Date: 28-01-2012



for Divi's Laboratories Limited

Dr. Murali K. Divi
Chairman & Managing Director

DIVI'S LABORATORIES LIMITED
Hyderabad

PRESS RELEASE dated 28th January , 2012

Divi's Labs earns an Income of Rs.417 crores in Q3 of FY11-12

Divi's Laboratories has earned a total income of Rs.417 crores on a stand-alone basis for the quarter ended 31st December, 2011 as against an income of Rs. 315 crores during the corresponding quarter last year. Profit before Tax (PBT) for the quarter grew by 38% to Rs.160 crores as against a PBT of Rs. 116 crores for the corresponding previous quarter. Profit after Tax (PAT) for the current quarter came to Rs.123 crores as against Rs. 102 crores during the corresponding previous quarter.

For the 9-month period ended 31st December, 2011, the company earned a total income of Rs.1134 crores as compared to Rs.834 crores during the corresponding 9-month period of last year. PBT for the current 9-month period came to Rs.423 crores as against a PBT of Rs.291 crores for the previous period. PAT for the current 9-months is Rs.331 crores as against Rs.261 crores for the previous period.

